GILD
GILEAD SCIENCES, INC.
Nasdaq: GILD · Foster City, CA · Healthcare
$129.31-1.55 (-1.18%)Closed
Market Cap$160.60B
Cash$5.43Bmost recent
Runwayprofitable
P/E (TTM)19.1EPS $6.78
52-Wk Range$107.48 – $153.91
Avg Volume7.1M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$129.31+79.0%
Pipeline

Drug candidates sponsored by GILEAD SCIENCES · ClinicalTrials.gov

71 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Tenofovir Disoproxil Fumarate
HIV Infections
Completed
2007-11past
3
Phase 4Truvada (TDF+FTC) alone
HIV Infections
Completed
2008-05past
1
Phase 4Truvada + Kaletra
HIV-1
Completed
2009-09past
1
Phase 4Ranolazine
Myocardial Perfusion Imaging+5 more
Completed
2015-02past
4
Phase 4Truvada (tenofovir DF + emtricitabine)
HIV Infections
Completed—1
Phase 4Viread
HIV Infections
Completed—1
Phase 4Ambisome
Invasive Aspergillosis
Completed—1
Phase 3Viread (tenofovir disoproxil fumarate)
HIV Infections
Completed
2001-12past
1
Phase 3Adefovir Dipivoxil for oral suspension, 2 mg/mL
Chronic Hepatitis B
Completed
2006-03past
1
Phase 3Ambrisentan
Pulmonary Hypertension+1 more
Completed
2008-07past
2
Phase 3Tenofovir DF
HIV Infections
Completed
2008-09past
1
Phase 3Darusentan
Hypertension
Terminated
2010-02past
1
Phase 3COBI
Acquired Immunodeficiency Syndrome+1 more
Completed
2012-08past
1
Phase 3E/C/F/TDF
Acquired Immunodeficiency Syndrome+1 more
Completed
2015-02-09past
2
Phase 2EVG/COBI/FTC/TDF
Acquired Immunodeficiency Syndrome+1 more
Completed
2015-10-22past
1
Phase 2Andecaliximab
Ulcerative Colitis+1 more
Terminated
2016-11-30past
2
Phase 3Eleclazine
Long QT Syndrome Type 3+1 more
Completed
2016-12-12past
2
Phase 3LDV/SOF
Hepatitis C Virus Infection+2 more
Completed
2017-07-08past
4
Phase 3E/C/F/TAF
HIV-1 Infection
Completed
2017-10-09past
1
Phase 3Filgotinib
Rheumatoid Arthritis
Completed
2018-03-20past
1
Phase 3F/TAF
Pre-Exposure Prophylaxis of HIV-1 Infection
Active, not recruiting
2019-01-31past
1
Phase 3SEL
Nonalcoholic Steatohepatitis
Terminated
2019-06-19past
1
Phase 3SOF/VEL
Hepatitis C Virus Infection
Completed
2019-11-19past
3
Phase 3seladelpar 5-10 mg
Primary Biliary Cholangitis
Completed
2020-02-16past
1
Phase 3Idelalisib
Chronic Lymphocytic Leukemia+3 more
Completed
2021-10-29past
4
Phase 3Seladelpar 10 mg
Primary Biliary Cholangitis
Completed
2023-08-11past
1
Phase 2Bictegravir
HIV-1-infection
Active, not recruiting
2025-10-27past
2
Phase 3Sacituzumab Govitecan-hziy
Metastatic Breast Cancer+4 more
Recruiting
2026-12
4
Phase 3Lenacapavir
HIV-1-infection
Not yet recruiting
2029-03
1
Phase 3Seladelpar
Primary Biliary Cholangitis+1 more
Recruiting
2030-08
2
Phase 3Unnamed
Lymphoma
Unknown—1
Phase 2Epratuzumab (hLL2- anti-CD22 humanized antibody)
Waldenstrom Macroglobulinemia
Terminated
2006-12past
1
Phase 2GS-9450
HCV Infection
Completed
2010-04past
2
Phase 1GS-9219
Non-Hodgkin's Lymphoma+2 more
Terminated
2010-07past
1
Phase 2Sofosbuvir
Hepatitis C Virus
Completed
2011-04past
1
Phase 2FTC/TDF
Chronic Hepatitis B
Completed
2011-05past
1
Phase 1CYT997
Glioblastoma Multiforme
Terminated
2011-06past
1
Phase 2GS-4774
Chronic HBV Infection
Completed
2014-09-09past
1
Phase 2Arhalofenate
Hyperuricemia+1 more
Completed
2014-12past
2
Phase 2GS-1101
Chronic Lymphocytic Leukemia
Withdrawn
2014-12past
1
Phase 2Arhalofenate 600 mg
Gout
Completed
2015-01past
1
Phase 2Simtuzumab
Idiopathic Pulmonary Fibrosis
Terminated
2016-02-19past
1
Phase 2Vesatolimod
Chronic Hepatitis B
Completed
2016-05-11past
1
Phase 2Selonsertib
Diabetic Kidney Disease
Completed
2016-07past
1
Phase 2Presatovir
Respiratory Syncytial Virus Infection
Completed
2017-03-27past
1
Phase 2SOF
Hepatitis C Virus+2 more
Completed
2017-11-30past
5
Phase 2SOF/VEL/VOX
Hepatitis C Virus Infection
Terminated
2019-12-04past
1
Phase 1Remdesivir (RDV)
COVID-19
Completed
2021-02-26past
1
Phase 2GS-5718
Rheumatoid Arthritis
Withdrawn
2023-02past
1
Phase 2Tenofovir Alafenamide
Chronic Hepatitis B
Completed
2024-01-23past
1
Phase 2Teropavimab
HIV-1 Infection
Active, not recruiting
2024-07-02past
1
Phase 2TAF
Chronic Hepatitis B
Active, not recruiting
2026-09
1
Phase 2Nelfinavir mesylate
HIV Infections
Completed—1
Phase 2Indinavir sulfate
HIV Infections
Completed—1
Phase 1CAL-263
Allergic Rhinitis
Completed
2010-04past
1
Phase 1RANEXA
Severe Renal Impairment
Terminated
2012-08past
1
Phase 1GS-5745 SC
Ulcerative Colitis
Completed
2014-10past
1
Phase 1GS-9901
Follicular Lymphoma+3 more
Terminated
2015-08past
1
Phase 1Voxilaprevir
HCV Infection
Completed
2015-09-28past
1
Phase 1GS-9820
Lymphoid Malignancies
Completed
2016-05past
1
Phase 1IMMU-114
Non-hodgkin's Lymphoma+5 more
Terminated
2017-03past
1
Phase 1CB-0406 100 mg
Healthy Volunteers
Completed
2021-05-30past
1
Phase 1Edecesertib
Cutaneous Lupus Erythematosus
Terminated
2022-10-18past
1
Phase 1Magrolimab
Hematological Malignancies
Terminated
2023-09-05past
1
Phase 1GS-0272
Rheumatoid Arthritis
Terminated
2026-05-11past
1
Phase 1Bulevirtide
Hepatic Impairment+2 more
Active, not recruiting
2028-07
2
Phase 1GS-0201
Advanced Solid Tumors
Recruiting
2028-09
1
Phase 1Cidofovir
HIV Infections+1 more
Completed—1
Phase 1Adefovir
HIV Infections
Completed—1
N/AUnnamed
HIV Infections+3 more
Completed
2011-03past
1
N/AUnnamed
HIV
Completed
2021-04-27past
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.